Reinhard Lohmann

1.1k total citations
29 papers, 754 citations indexed

About

Reinhard Lohmann is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Reinhard Lohmann has authored 29 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Hematology. Recurrent topics in Reinhard Lohmann's work include HER2/EGFR in Cancer Research (5 papers), Melanoma and MAPK Pathways (4 papers) and Cutaneous Melanoma Detection and Management (3 papers). Reinhard Lohmann is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Melanoma and MAPK Pathways (4 papers) and Cutaneous Melanoma Detection and Management (3 papers). Reinhard Lohmann collaborates with scholars based in Canada, Germany and United Kingdom. Reinhard Lohmann's co-authors include Elizabeth A. Eisenhauer, Nancy Wainman, Ian Quirt, Andrew Belch, Joseph M. Connors, Pedro López, Ralph M. Meyer, C. Tom Kouroukis, Michael Crump and Robert Turner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Reinhard Lohmann

28 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reinhard Lohmann Canada 11 388 329 135 116 112 29 754
Mercè de Frías Spain 13 237 0.6× 511 1.6× 94 0.7× 43 0.4× 103 0.9× 17 734
Anne Keating United States 13 409 1.1× 638 1.9× 90 0.7× 192 1.7× 130 1.2× 26 899
Andrew Dorr United States 16 356 0.9× 737 2.2× 86 0.6× 147 1.3× 64 0.6× 37 1.0k
Divis Khaira United States 8 393 1.0× 378 1.1× 46 0.3× 101 0.9× 239 2.1× 8 784
D. Gandara United States 11 377 1.0× 478 1.5× 53 0.4× 203 1.8× 85 0.8× 26 837
Eftihia Cocolakis Canada 12 342 0.9× 898 2.7× 69 0.5× 64 0.6× 123 1.1× 20 1.2k
Kilannin Krysiak United States 13 240 0.6× 371 1.1× 228 1.7× 64 0.6× 105 0.9× 26 794
Nikhil Mukhi United States 7 367 0.9× 398 1.2× 283 2.1× 71 0.6× 159 1.4× 14 891
Eva Groß Germany 18 445 1.1× 547 1.7× 118 0.9× 90 0.8× 49 0.4× 34 968
Shane K. Green Canada 7 378 1.0× 462 1.4× 51 0.4× 117 1.0× 90 0.8× 9 795

Countries citing papers authored by Reinhard Lohmann

Since Specialization
Citations

This map shows the geographic impact of Reinhard Lohmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reinhard Lohmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reinhard Lohmann more than expected).

Fields of papers citing papers by Reinhard Lohmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reinhard Lohmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reinhard Lohmann. The network helps show where Reinhard Lohmann may publish in the future.

Co-authorship network of co-authors of Reinhard Lohmann

This figure shows the co-authorship network connecting the top 25 collaborators of Reinhard Lohmann. A scholar is included among the top collaborators of Reinhard Lohmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reinhard Lohmann. Reinhard Lohmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lohmann, Reinhard, et al.. (2008). Profiency testing in reticulocyte counting. Clinical & Laboratory Haematology. 16(1). 57–64. 2 indexed citations
2.
Chin‐Yee, Ian, Michael Keeney, & Reinhard Lohmann. (2008). Flow cytometric reticulocyte analysis using thiazole orange; clinical experience and technical limitations. Clinical & Laboratory Haematology. 13(2). 177–188. 9 indexed citations
3.
Temple, Claire, Jeremy Parfitt, David T. Shum, et al.. (2007). Clinical significance of the RT‐PCR positive sentinel node in melanoma. Journal of Surgical Oncology. 95(7). 546–554. 6 indexed citations
4.
Ernst, D. Scott, Elizabeth A. Eisenhauer, Nancy Wainman, et al.. (2005). Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma. Investigational New Drugs. 23(6). 569–575. 89 indexed citations
5.
Burdette-Radoux, Susan, Richard Tozer, Reinhard Lohmann, et al.. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational New Drugs. 22(3). 315–322. 72 indexed citations
6.
Quirt, Ian, A. Bodurtha, Reinhard Lohmann, et al.. (2002). Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 20(4). 431–437. 35 indexed citations
7.
Tozer, Richard, Susan Burdette-Radoux, M. L. Davis, et al.. (2002). A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study. Investigational New Drugs. 20(4). 407–412. 18 indexed citations
8.
Temple, Claire, et al.. (2000). Sentinel Node Biopsy in Melanoma Using Technetium-99m Rhenium Colloid: The London Experience. Annals of Plastic Surgery. 45(5). 491–499. 6 indexed citations
9.
Bélanger, K., Richard Tozer, Susan Burdette-Radoux, et al.. (1999). Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule. European Journal of Cancer. 35. S374–S374. 2 indexed citations
10.
Lohmann, Reinhard, et al.. (1996). Oral indomethacin and ranitidine in advanced melanoma: A phase II study. Clinical Oncology. 8(2). 112–115. 7 indexed citations
11.
12.
Goss, Glenwood, et al.. (1995). Didemnin B in favourable histology non-Hodgkin's lymphoma. Investigational New Drugs. 13(3). 257–260. 9 indexed citations
13.
Lohmann, Reinhard, Gisbert Schneider, Dirk Behrens, & Paul Wrede. (1994). A neural network model for the prediction of membrane‐spanning amino acid sequences. Protein Science. 3(9). 1597–1601. 34 indexed citations
14.
Lohmann, Reinhard, et al.. (1993). Digital Systems and Structure Evolution. Journal of the Audio Engineering Society.
15.
Shore, Tsiporah B., Elizabeth A. Eisenhauer, Ian Quirt, et al.. (1993). A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: A study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG). Annals of Oncology. 4(8). 695–696. 3 indexed citations
16.
Lohmann, Reinhard. (1992). Structure Evolution and Incomplete Induction.. 177–188. 6 indexed citations
17.
Chin‐Yee, Ian, Arthur T. Porter, & Reinhard Lohmann. (1991). Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma. Clinical Oncology. 3(5). 288–290. 1 indexed citations
18.
Toffelmire, Edwin B., et al.. (1979). PLASMA EXCHANGE IN THROMBOTIC THROMBOCYTOPENIC PURPURA. The Lancet. 313(8125). 1065–1066. 5 indexed citations
19.
Spiro, Stephen, D. A. G. Galton, E. Wiltshaw, & Reinhard Lohmann. (1975). Follicular lymphoma: A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukaemia.. PubMed. 2. 60–72. 33 indexed citations
20.
Lohmann, Reinhard, et al.. (1952). Elektrencephalographische Untersuchungen am Kaninchen nach Ausschaltung des Corpus geniculatum laterale einer Seite. Journal of Neurology. 167(6). 542–557. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mercè de Frías Breakdown of academic impact, for papers by Anne Keating Breakdown of academic impact, for papers by Andrew Dorr Breakdown of academic impact, for papers by Divis Khaira Breakdown of academic impact, for papers by D. Gandara Breakdown of academic impact, for papers by Eftihia Cocolakis Breakdown of academic impact, for papers by Kilannin Krysiak Breakdown of academic impact, for papers by Nikhil Mukhi Breakdown of academic impact, for papers by Eva Groß Breakdown of academic impact, for papers by Shane K. Green
Rankless by CCL
2026